Ronald Drengler

Statistics

Publications

Citations

1.6K

H-Index

Active since

1995

Affiliations

The University of Texas at San Antonio Health Science Center(Current)

Brooke Army Medical Center

South Texas Accelerated Research Therapeutics

Texas Oncology

Merck & Co., Inc., Rahway, NJ, USA (United States)

Ronald Drengler is an author at The University of Texas at San Antonio Health Science Center specializing in medicine, pharmacology, and pharmacokinetics of anticancer drugs.

Publications per year

1995–2024

Publications

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, Soonmo Peter Kang, Drew Rasco et al. · Clinical Cancer Research · 2015 · 794 citations

Medicine, Oncology, Pharmacology +17

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

Eric K. Rowinsky, Lee Smith, Y M Wang et al. · Journal of Clinical Oncology · 1998 · 146 citations

Medicine, Oncology, Pharmacology +17

Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors

Ronald Drengler, John G. Kuhn, Larry J. Schaaf et al. · Journal of Clinical Oncology · 1999 · 94 citations

Medicine, Pharmacokinetics, Pharmacology +16

Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.

Amita Patnaik, Soonmo Peter Kang, Anthony W. Tolcher et al. · Journal of Clinical Oncology · 2012 · 81 citations

Medicine, Oncology, Pharmacology +17

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid Malignancies

Miguel A. Villalona‐Calero, Geoffrey R. Weiss, Howard A. Burris et al. · Journal of Clinical Oncology · 1999 · 72 citations

Medicine, Oncology, Pharmacology +17

1–5 of 18